Last $5.20 USD
Change Today -0.20 / -3.70%
Volume 29.1K
DHRM On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

dehaier medical systems ltd (DHRM) Snapshot

Open
$5.31
Previous Close
$5.40
Day High
$5.37
Day Low
$5.20
52 Week High
02/20/14 - $12.89
52 Week Low
08/14/13 - $1.82
Market Cap
29.2M
Average Volume 10 Days
82.0K
EPS TTM
$0.71
Shares Outstanding
5.6M
EX-Date
--
P/E TM
7.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for DEHAIER MEDICAL SYSTEMS LTD (DHRM)

Related News

No related news articles were found.

dehaier medical systems ltd (DHRM) Related Businessweek News

No Related Businessweek News Found

dehaier medical systems ltd (DHRM) Details

Dehaier Medical Systems Limited, through its subsidiaries, develops and distributes medical devices, and sleep respiratory and oxygen therapy products in the People’s Republic of China. Its proprietary products include medical devices and related supporting/technical service products, such as mobile medical X-ray image devices, anesthesia machines, ventilator air compressors, trolleys for ventilators, sterilizers for ventilators, ultrasonic nebulizers, laryngoscopes, and oxygen valves; and sleep respiratory and oxygen therapy products, which consist of oxygen concentrating products, sleep apnea treatment products, sleep apnea diagnostic products, and effective oxygen supplement systems. The company sells its products primarily through distributors, as well as directly to hospitals, clinics, government health bureaus, government organizations, and individuals. Dehaier Medical Systems Limited was incorporated in 2003 and is headquartered in Beijing, the People’s Republic of China.

104 Employees
Last Reported Date: 04/1/14
Founded in 2003

dehaier medical systems ltd (DHRM) Top Compensated Officers

Chairman, Chief Executive Officer and General...
Total Annual Compensation: $29.7K
Compensation as of Fiscal Year 2013.

dehaier medical systems ltd (DHRM) Key Developments

Dehaier Medical Systems Ltd. Receives CFDA Approval for Morpheus Ox Sleep Diagnostic Software

Dehaier Medical Systems Ltd. announced that received approval from the China Food and Drug Administration for its Morpheus Ox software. The company applied to the CFDA to register the Morpheus Ox in July 2013. With completion of this registration, the company has collected all certifications for four key components of Dehaier's Sleep Respiratory Solutions: the second generation DHR998 Sleep Diagnostic Device, photoplethysmography (PPG) sensor, sleep diagnostic software and continuous positive airway pressure ventilator in order to establish a comprehensive product line for Obstructive Sleep Apnea. The company's Morpheus Ox products assist with the diagnosis of sleep apnea, provide treatment options to apnea patients and allow post-treatment evaluation services to pinpoint further opportunities for improvement.

Dehaier Medical Systems Limited Acquires Multiple International Players Authorization for Chinese Government Procurement

Dehaier Medical Systems Ltd. announced that it will serve as the exclusive product-appointed distribution agent for some of the medical equipment companies in bidding for multiple government procurement projects in China, the procurement projects the company is bidding for are designated by these companies. The appointed products the company is authorized for the procurement include Harmonic System from Johnson & Johnson Medical (Shanghai) Ltd., the MasterScreen(TM) pulmonary function testing system from CareFusion (Shanghai) Commercial and Trading Co. Ltd., ventilator from Weinmann GmbH + Co. KG, infusion pump from B. Braun Medical (Shanghai) International Trading Co. Ltd., spectrophotometer from Shimadzu (China) Co. Ltd. and portable color Doppler ultrasound, versatile anesthesia machine and multi-parameter monitor from Mindray Medical International Limited. The aggregate value of the procurement projects is expected to be approximately $21 million.

Dehaier Medical Systems Ltd. Announces Management Changes

Dehaier Medical Systems Ltd. announced that it has appointed Huili (Alisa) Li as its new Chief Financial Officer and as a Director, in both cases to replace Mr. Jingli (Charles) Li, who resigned on April 8, 2014. Mr. Li resigned these positions solely for personal reasons and not due to any disagreement with the company. Alisa Li will serve the remainder of Charles Li's term as Director, which term expires in 2014 and will face re-election at its annual general meeting of shareholders in 2014. Alisa Li has served as the company's financial manager since 2013. She previously worked as an auditor in the professional services department of LehmanBrown's Beijing office from 2010 to 2013 and in the assurance department of the Beijing office of PricewaterhouseCoopers (PwC) from 2007 to 2009. Ms. Li has been chosen to serve as a director because of her experience with financial matters and her familiarity with the company's operations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DHRM:US $5.20 USD -0.20

DHRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covidien PLC $91.00 USD +0.09
Draegerwerk AG & Co KGaA €72.00 EUR +0.61
Jiangsu Yuyue Medical Equipment & Supply Co Ltd CNY26.04 CNY +0.69
Koninklijke Philips NV €23.19 EUR +0.045
ResMed Inc $49.59 USD +0.23
View Industry Companies
 

Industry Analysis

DHRM

Industry Average

Valuation DHRM Industry Range
Price/Earnings 12.7x
Price/Sales 1.5x
Price/Book 0.7x
Price/Cash Flow 15.2x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEHAIER MEDICAL SYSTEMS LTD, please visit www.dehaier.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.